Clinical Study of Moxifloxacin in Treatment of Elderly Patients with Community Acquired Pneumonia
Abstract
Objective:To evaluate the clinical efficacy and safety of moxifloxacin in the treatment of elderly patients with moderate to severe community acquired pneumonia.Methods: Elderly patients with moderate to severe community acquired pneumonia were treated with moxifloxacin or ceftriaxone sodium in a randomized controlled study.Results:A total of 117 patients were enrolled in this study,59 patients in moxifloxacin group,58 patients in ceftriaxone sodium group.The cure rates and the effective rates of moxifloxacin group and ceftriaxone sodium group were 49.15%,37.93%(P0.05) and 88.14%,65.52%(P0.05)respectively.The rates of adverse reaction in the two groups were 8.47% and 6.90%(P0.05)respectively.Conclusion:Moxifloxacin is effective and safe for the treatment of elderly patients with moderate to severe community acquired pneumonia.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 117 participants or records.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.